FUJIFILM Diosynth Biotechnologies signed a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals to provide U.S.-based production of its biologic medicines.
FUJIFILM will provide U.S.-based manufacturing for Regeneron over the 10-year period through current and planned expansions at its new large-scale biopharmaceutical manufacturing facility in Holly Springs, NC, when the site begins operations later this year.
“FUJIFILM Diosynth Biotechnologies will be bringing additional capacity online in 2025, 2026, and beyond as it completes the current $7 billion of expansion projects underway in both Europe and the United States,” said Toshihisa Iida, director, corporate vp, general manager of life sciences strategy headquarters and Bio-CDMO division, FUJIFILM, Japan.
“We are delighted to be selected as the manufacturing supply partner for Regeneron, utilizing our new facility in Holly Springs. The Holly Springs site is part of our kojoX
interconnected manufacturing network, which provides a first-of-its-kind modular approach with standardized equipment, processes, and procedures across our sites around the globe to help ensure supply chain security and seamless tech transfers,” noted Lars Petersen, president and CEO, FUJIFILM Diosynth Biotechnologies.
“We take our role seriously, and our decision to work with FUJIFILM Diosynth Biotechnologies reflects our belief that they will meet our high standards and grow with us,” added Daniel Van Plew, executive vp and general manager, industrial operations and product supply at Regeneron. “As the U.S. is the largest market for biopharmaceuticals, FUJIFILM has made significant investments in the U.S. of about $4 billion in building biopharmaceutical manufacturing sites, life sciences capabilities, and growing its technical talent.
“Additionally, through our previously announced expansion efforts, we are pleased to share that we’ve already added 500 new positions as part of our overall goal of creating 1,400 new jobs in North Carolina by 2031.”
The post FUJIFILM Diosynth Biotechnologies and Regeneron Sign 10-year, $3+ Billion U.S. Manufacturing Deal appeared first on GEN - Genetic Engineering and Biotechnology News.
FUJIFILM will provide U.S.-based manufacturing for Regeneron over the 10-year period through current and planned expansions at its new large-scale biopharmaceutical manufacturing facility in Holly Springs, NC, when the site begins operations later this year.
“FUJIFILM Diosynth Biotechnologies will be bringing additional capacity online in 2025, 2026, and beyond as it completes the current $7 billion of expansion projects underway in both Europe and the United States,” said Toshihisa Iida, director, corporate vp, general manager of life sciences strategy headquarters and Bio-CDMO division, FUJIFILM, Japan.
“We are delighted to be selected as the manufacturing supply partner for Regeneron, utilizing our new facility in Holly Springs. The Holly Springs site is part of our kojoX
“We take our role seriously, and our decision to work with FUJIFILM Diosynth Biotechnologies reflects our belief that they will meet our high standards and grow with us,” added Daniel Van Plew, executive vp and general manager, industrial operations and product supply at Regeneron. “As the U.S. is the largest market for biopharmaceuticals, FUJIFILM has made significant investments in the U.S. of about $4 billion in building biopharmaceutical manufacturing sites, life sciences capabilities, and growing its technical talent.
“Additionally, through our previously announced expansion efforts, we are pleased to share that we’ve already added 500 new positions as part of our overall goal of creating 1,400 new jobs in North Carolina by 2031.”
The post FUJIFILM Diosynth Biotechnologies and Regeneron Sign 10-year, $3+ Billion U.S. Manufacturing Deal appeared first on GEN - Genetic Engineering and Biotechnology News.